Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL

Sponsor
The First Affiliated Hospital of Xiamen University
Study ID
NCT06151080
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Lenalidomide combined with G-CHOP (LO CHOP) — DRUG
    Lenalidomide combined with G-CHOP to treat newly diagnosed diffuse large B-cell lymphoma with follicular lymphoma (CDLBCL-FL)

Study Details

To evaluate the efficacy and adverse effects of lenalidomide combined with G-CHOP(LO-CHOP) in the treatment of newly diagnosed diffuse large B-cell lymphoma with follicular lymphoma (CDLBCL-FL).

Key Dates

First listed
Nov 30, 2023
Start date
Nov 22, 2023
Status verified
Feb 2025
Primary completion
Aug 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
38 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: LO-CHOP
    Lenalidomide combined with G-CHOP

Primary Outcome Measure

Complete remission rate [ Time Frame: Up to 28 months ]

Central Contacts

Related Studies